ArticleMolecular medicine (Cambridge, Mass.)2026
Nestin promotes imatinib resistance in gastrointestinal stromal tumors by enhancing PINK1-dependent mitophagy.
Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundGastrointestinal stromal tumors (GIST) frequently develop secondary resistance to imatinib, which represents a major obstacle to achieving durable clinical benefit. However, the molecular mechanisms underlying acquired resistance remain poorly understood. Nestin, a cytoskeletal protein, has been implicated in tumor progression and cellular stress responses, but its role in imatinib-resistant GIST has not been fully elucidated.
methodsPatient tumor specimens, imatinib-resistant GIST cell lines, and xenograft mouse models were analyzed to evaluate Nestin expression. Functional studies were performed using RNA interference-mediated silencing of Nestin. Mitophagy flux assays were conducted to evaluate mitochondrial quality control. The effects of Nestin modulation on PINK1 stability, mitophagy activity, mitochondrial integrity, and imatinib sensitivity were evaluated both in vitro and in vivo. Clinical correlations between Nestin expression, therapeutic response, and prognosis were also analyzed.
resultsNestin expression was significantly upregulated in imatinib-resistant GIST across patient samples, resistant cell lines, and xenograft models. Mechanistically, Nestin stabilized PINK1, thereby enhancing PINK1-dependent mitophagy and preserving mitochondrial integrity under imatinib-induced stress. RNA interference suppression of Nestin reduced PINK1 accumulation, impaired mitophagy, increased mitochondrial damage, and restored imatinib sensitivity in vitro and in vivo. Clinically, elevated Nestin expression was associated with poor therapeutic response and unfavorable prognosis.
conclusionsThe Nestin-PINK1 axis is a critical driver of imatinib resistance in GIST. Targeting Nestin-mediated mitophagy may represent a promising therapeutic strategy to overcome imatinib resistance and improve clinical outcomes in patients with GIST.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.